Lumos Secures Further US Medicare Reimbursement for FebriDx
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Lumos Diagnostics Holdings Ltd. has announced that it secured additional Medicare reimbursement coverage for its FebriDx test from two more Medicare Administrative Contractors, enhancing its market access in the U.S. This coverage now includes four out of seven MACs, representing a significant portion of U.S. Medicare payment coverage, which is crucial for the commercial success of FebriDx. The company aims to continue negotiations with the remaining MACs and pursue private payor reimbursement to achieve nationwide access for patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Lumos Diagnostics Holdings Ltd. on 6ix
Story so far
Earlier from Lumos Diagnostics
- Lumos Secures Key US Reimbursement Milestones for FebriDx
- Hologic Development Agreement Expanded Scope of Works
- Commencement of FebriDx CLIA Waiver Study
- Lumos receives CPT PLA Code for FebriDX in the US
- Lumos Successfully Completes Retail Entitlement Offer
Later from Lumos Diagnostics
- Lumos Advances FebriDx Sales with iMedical Purchase Order
- Lumos Secures Fifth US Medicare Reimbursement for FebriDx
- Lumos Secures Sixth US Medicare Reimbursement for FebriDx
- Lumos Reaches Recruitment Milestone in FebriDx Study
- Lumos Reaches FebriDx CLIA Waiver Study Enrolment Milestone
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics